EGFR and non-small cell lung carcinoma: In 2016, the Food and Drug Administration (FDA) firstly approved the use of ctDNA as a liquid biopsy test for patients with stage IV non-small cell lung cancer (NSCLC) to check for epidermal growth factor receptor (EGFR) mutations [30].